Transcription of Muscle Actin Genes by a Nuclear Form of Mitochondrial RNA Polymerase by Lee, Yu-Ling et al.






1Institute of Biochemistry and Molecular Biology, School of Life Science, National Yang-Ming University, Taipei, Taiwan, 2VGH Yang-Ming Genome Research Center,
National Yang-Ming University, Taipei, Taiwan
Abstract
Actins are the major constituent of the cytoskeleton. In this report we present several lines of evidence that muscle actin
genes are transcribed by nuclear isoform of mitochondrial RNA polymerase (spRNAP-IV) whereas the non-muscle actin
genes are transcribed by the conventional RNA polymerase II (PolII). We show that mRNA level of muscle actin genes are
resistant to PolII inhibitors a-amanitin and triptolide as well as insensitive to knockdown of PolII but not to knockdown of
spRNAP-IV, in contrast to non-muscle actin genes in several cell lines. Similar results are obtained from nuclear run-on
experiments. Reporter assay using muscle actin or PolII gene promoters also demonstrate the differential sensitivity to PolII
inhibitors. Finally, chromatin-immunoprecipitation experiment was used to demonstrate that spRNAP-IV is associated with
promoter of muscle actin genes but not with that of non-muscle gene and knockdown of spRNAP-IV depleted this
polymerase from muscle actin genes. In summary, these experiments indicate that the two types of actin genes are
transcribed by different transcription machinery. We also found that POLRMT gene is transcribed by spRNAP-IV, and actin
genes are sensitive to oligomycin, suggesting a transcription coupling between mitochondria and nucleus.
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Introduction
Transcription of mRNA in eukaryotes is generally performed by
RNA polymerase II (PolII), one of the three nuclear RNA
polymerases. Kravchenko et al., however, reported in 2005 that a
fourth nuclear RNA polymerase, spRNAP-IV, also participated in
the transcription of some of the nuclear mRNAs of HeLa cells [1].
spRNAP-IV and the mitochondria-targeting RNA polymerase
mtRNAP are both single-polypeptide enzymes encoded by the
POLRMT gene by differential splicing, but the former lacks the N-
terminal 262-amino acids of the latter, and thus the mitochondrial
targeting signal. The nature of genes transcribed by spRNAP-IV
remains largely unknown. Furthermore, in the previous study the
involvement of spRNAP-IV in nuclear mRNA transcription was
largely based on a comparison of mRNA levels in cells treated and
untreated with a PolII inhibitor a-amanitin. Because levels of specific
mRNAs can also be affected by RNA processing and turnover, there
is considerable uncertainty whether the observed differences were
indeed due to transcription by the a-amanitin-resistant spRNAP-IV.
During our transcriptome analysis of MCF-7 cells using
microarray, we observed that there were over 800 genes resistant
to both PolII inhibitors, a-amanitin and triptolide [2,3], and up-
regulated more than two folds in terms of mRNA expression level.
However, only one third of these genes were actually found to be
insensitive to PolII knockdown and down-regulated by knockdown
of spRNAP-IV in microarray analyses. To test which genes out of
this subset of human genes are truly transcribed by spRNAP-IV
but not by PolII, we chose a few genes for further investigation
using nuclear run-on and knockdown to rule out RNA stability
and processing. Among these genes we noticed that muscle actins
as a group, in contrast to non-muscle actin genes, are resistant to
both inhibitors of PolII and PolII knockdown as well as sensitive to
spRNAP-IV knockdown. Here we present our study of the
transcription of the actin group of genes, and show that those
encoding for smooth, cardiac and skeletal actins are indeed
transcribed by spRNAP-IV, but those non-muscle actins are
transcribed by PolII. We also found that the nuclear POLRMT
gene itself is transcribed by spRNAP-IV, suggesting a plausible
transcription coupling between nucleus and mitochondria. Our
results support a new mechanism of transcription of a subset of
nuclear genes using the fourth RNA polymerase spRNAP-IV.
Results
Muscle and non-muscle actin genes show differential
sensitivity to RNA polymerase II inhibitors
The actin group of genes can be classified into muscle actins and
non-muscle actins. The muscle actins include cardiac, smooth, and
skeletal muscle actins encoded by genes ACTC1, ACTG2, ACTA2,
and ACTA1. The non-muscle type actins include genes such as
ACTG1, ACTB, ACTN1, ACTL6A, and ACTL8T. In the microarray
analysis we found that muscle actin genes were resistant to PolII
inhibitor a-amanitin in contrast to non-muscle actin genes which
were sensitive. We then performed q-PCR analysis to confirm
these results (Figure 1A; effect of different concentrations of a-
amanitin is shown in S1A). The q-PCR analysis even indicated
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treatment whereas cytoplasmic actin genes were inhibited. As
expected, PolII, transcription factor TAF5 as well as GAPDH were
sensitive to this drug.
We further confirmed resistance of muscle actin expression to
PolII inhibition using another PolII inhibitor, triptolide (Figure 1B;
effect of different concentrations of triptolide is shown in S2B).
These results suggest that the two types of actin genes are
transcribed by different transcription mechanisms. Interestingly,
vascular smooth muscle ACTA2 gene has two different promoters
and the short form, NM_001613 (here after referred to as ACTA2-S)
is resistant, but the long form, NM_001141945 (here after referred
to as ACTA2-L) is sensitive to a-amanitin and triptolide in MCF-7
cell line. The resistance of muscle actin genes to triptolide treatment
was also observed in MCF-10F, MBA-MD-231, MDA-MB-435s
and human umbilical vein smooth muscle cells (HUVSMC) cells
(Figure S1C - F). Strong induction of muscle actin genes by TNF-a
was also found to be resistant to PolII inhibitors (Figure S2).
To further demonstrate insensitivity of muscle actin gene
expression to a-amanitin, we analyzed the level of mRNA in cells
treated with increasing amount of the drug (Figure 1C). The result
clearly showed that the muscle actin genes ACTG2, ACTA2-S,
ACTC1, and ACTA1 were resistant or even up-regulated with
increasing amount of a-amanitin, whereas the non-muscle genes,
ACTB and ACTA2-L, were sensitive to the drug. The mitochon-
drial RNA polymerase spRNAP-IV and mitochondria encoded
cytochrome b were resistant to the drug whereas TAF5 and
GAPDH were sensitive to a-amanitin inhibition.
Expression of muscle actin genes was resistant to
knockdown to PolII but sensitive to POLRMT knockdown
The results described above suggest that muscle actin genes are not
transcribed by PolII. To test this hypothesis, we carried out analysis of
muscle and non-muscle actin mRNA 72 hours after knockdown of
PolII. The results showed that muscle actin genes ACTG2, ACTA2-S,
ACTC1, ACTA1 as well as mitochondria cytochrome b were insensitive
to PolII knockdown, whereas ACTB, ACTA2-L and TAF5 were down-
regulated after knockdown in both MCF-7 and HUVSMC cells
(Figure 2A and 2B). This result further demonstrates that muscle actin
genes are not transcribed by PolII. As Kravchenko et al., have shown
that a differentially spliced mitochondrial RNA polymerase spRNAP-
IV is involved in the transcription of some nuclear genes resistant to a-
amanitin [1], we then tested whether muscle actin genes were
transcribed by this polymerase. Indeed, muscle actin genes expression
was down-regulated after POLRMT knockdown but not non-muscle
actin genes in both MCF-7 and HUVSMC cell lines (Figure 2C and
2D). These results further support the hypothesis that muscle actin
genes are transcribed by spRNAP-IV, whereas the non-muscle actin
genes are transcribed by PolII.
Nuclear run-on transcription of muscle actin genes were
resistant to a-amanitin and triptolide treatments and
PolII knockdown but down-regulated after spRNAP-IV
knockdown
Since mRNA level can be affected by transcription, post-
transcriptional processing or RNA stability, resistance of expres-
Figure 1. Muscle actin genes are resistant and stimulated by a-amanitin and triptolide. (A) Quantitative RT-PCR of actin genes in MCF-7
cells treated with or without 10 mg/ml of a-amanitin for 48 h. A relative expression normalized over 28s is displayed. (N=3, mean 6 S.D.) (B)
Quantitative RT-PCR of actin genes in MCF-7 cells treated with or without 0.3 mM of triptolide for 24 h. A relative expression normalized over GAPDH
is displayed. (N=3, mean 6 S.D.) (C) RT-PCR of actin genes in MCF-7 cells treated with increasing concentration of a-amanitin for 48 h showing
concentration- dependent stimulation of muscle actin transcripts.
doi:10.1371/journal.pone.0022583.g001
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transcription. To demonstrate that inhibition indeed occurs at
transcriptional level, we carried out nuclear run-on experiment
after cells were treated with PolII inhibitors. The run-on RNA was
labeled with biotin and the run-on products were affinity purified.
The nature of the affinity-purified nascent RNA was then analyzed
by RT-PCR reaction. The results showed that expression of
muscle actin ACTG2 and ACTA2-S as well as spRNAP-IV were
indeed induced by a-amanitin and triptolide, whereas ACTB,
ACTA2-L, and TAF5 were down-regulated (Figure 3A, 3B, and
3D) in both MCF-7 and HUVSMC cells. Control experiments
without biotin labeling did not show the run-on products
(Figure 3C and 3E).
We also carried out nuclear run-on after knockdown of either
PolII or POLRMT. PolII knockdown led to decreased run-on
product of ACTB and TAF5 but not muscle actin genes ACTG2
and ACTA2-S. On the contrary, knockdown of POLRMT inhibited
muscle actin gene transcription but not the transcription of non-
muscle genes (Figure 3F).
Presence of manganese ions inhibits in vitro RNA
synthesis performed by spRNAP-IV
Since mitochondrial RNA polymerase is known to be inhibited
by manganese whereas PolII can transcribe in the presence of this
divalent ion [4], muscle actin gene transcription in vitro would be
inhibited by manganese if spRNAP-IV is involved in the
transcription of these genes. Nuclear run-on experiments indeed
confirm that ACTG2, ACTA2-S and spRNAP-IV are down-
regulated in the presence of manganese. In contrast, ACTB, TAF5
and ACTA2-L, which are PolII genes, are not affected by this
divalent ion (Figure 3G).
Reporter expression driven by ACTG2 and ACTA2-S
promoter was resistant to triptolide treatment
We employed promoter-driven reporter assay to further
demonstrate that muscle actin genes are not transcribed by PolII.
The upstream promoter regions of ACTG2, ACTA2-S, and TAF5
genes were cloned into a reporter plasmid pGL3. ACTG2 and
ACTA2-S promoter-driven luciferase activity showed resistant or
even up-regulated by triptolide treatment whereas TAF5 promoter
showed a decrease in luciferase activity after triptolide treatment
(Figure 4A). These results further support thehypothesisthat muscle
actin genes are transcribed not by PolII but by spRNAP-IV.
Muscle actin gene promoter transcribed in vitro
transcription using HeLa cell extract is sensitive to
antibody to spRNAP-IV but not antibody to PolII
In vitro transcription of ACTG2 and TAF5 promoters were further
assayed to demonstrate that ACTG2 is not transcribed by PolII, but
by spRNAP-IV. The pGL3 plasmids containing either upstream
promoter regions of ACTG2 and TAF5 genes used in Luciferase
assay were digested into linear forms to serve as DNA template in in
Figure 2. Muscle actin genes are resistant to PolII knockdown, but sensitive to POLRMT knockdown. Quantitative RT-PCR of actin genes
in (A) MCF-7 cells and (B) HUVSMC cells subjected to siRNA knockdown of PolII for 72 h. A relative expression normalized over 28s is displayed. (N=3,
mean 6 S.D.) Quantitative RT-PCR of actin genes in (A) MCF-7 cells and (B) HUVSMC cells subjected to siRNA knockdown of POLRMT for 72 h. A
relative expression normalized over GAPDH is displayed. (N=3, mean 6 S.D.)
doi:10.1371/journal.pone.0022583.g002
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transcription activity of ACTG2 was down-regulated in the presence
of antibodies to mitochondrial RNA polymerase, but not to PolII
antibody (Figure 4B). In contrast, the in vitro transcription activity of
TAF5 was significantly down-regulated in the presence of PolII
antibody, but not mitochondrial RNA polymerase antibodies.
These results further support the hypothesis that muscle actin genes
are transcribed not by PolII but by spRNAP-IV.
Direct binding of spRNAP-IV to muscle actin gene
promoter regions
We employed chromatin immunoprecipitation (ChIP) to
determine whether spRNAP-IV binds directly to the promoter
regions of ACTG2 and ACTA2-S. As shown in Figure 5, ChIP
experiments showed that spRNAP-IV binds to promoter regions
of ACTG2 and ACTA2-S but not ACTB and TAF5, and that the
promoter binding is insensitive to triptolide treatment in both
Figure 3. Nuclear Run-on assay of muscle actin genes transcription. (A) MCF-7 cells were treated with or without 10 mg/ml of a-amanitin for
48 h. (B) MCF-7 cells were treated with or without 0.3 mM of triptolide for 24 h (C) Run-on reaction was performed omitting biotinylated nucleotides
as negative control in MCF-7 cells (D) HUVSMC cells were treated with or without 0.3 mM of triptolide for 24 h. (E) Run-on reaction was performed
omitting biotinylated nucleotides as negative control in HUVSMC cells. (F) MCF-7 cells were subjected to siRNA knockdown of either non-targeting
control (labeled C), PolII (labeled siII) or POLRMT (labeled siMt) for 72 h. (G) Nuclei were prepared and run-on reaction was performed either without
(ctrl) or with the presence of 2 mM of Manganese ion (Mn). Nuclei were prepared and run-on reaction was performed by incubation with GTP, CTP,
ATP, and biotin-16-UTP. Total RNA was prepared and biotinylated RNA was isolated using streptavidin magnetic beads (Run-on RNA). ACTG2, ACTA2-
S, ACTA2-L, spRNAP-IV, ACTB, TAF5, and 28S RNA levels in total RNA (Total RNA in black), biotinylated RNA (Run-on RNA in red), and unlabeled RNA
(Run-on RNA (-) in red) were determined by RT-PCR. (M: marker; Ctrl: control; 10a:1 0mg/ml of a-amanitin; Trip: 0.3 mM of triptolide; siC: knockdown
control; siMT: knockdown POLRMT; siII: knockdown PolII; Mn: 2 mM of Mn ion).
doi:10.1371/journal.pone.0022583.g003
Figure 4. Reporter and in vitro transcription assays of muscle actin gene promoters. Promoter regions of ACTG2, ACTA2-S, and TAF5 were
constructed and cloned into the pGL3-basic reporter plasmid. (A) Luciferase activity assays were performed with transient transfections of pGL3-basic,
pGL3-ACTA2-S-promoter, pGL3-ACTG2-promoter, and pGL3-TAF5-promoter treated with or without 0.3 mM of triptolide for 24 h. pGL3-basic was
used as control and the relative fold change of luciferase activity of each gene was shown. (N=3, mean 6 S.D.) (B) pGL3-ACTA2-S-promoter and
pGL3-ACTG2-promoter plasmids were digested into linear forms by NotI. In vitro transcription assays were performed by using the HeLaScribe
R
Nuclear Extract in vitro Transcription System (Promega). Anti-RNA polymerase II (PolII), anti-mitochondrial RNA polymerase (mtRNAP-1 and mtRNAP-
2) and Anti-IgG (IgG) antibodies were each pre-incubated with nuclear extract. In vitro transcription was performed by incubation with GTP, CTP, ATP,
and biotin-16-UTP. Negative control (Negative) was performed by incubation with non biotin labeled NTPs. Total RNA was prepared and biotinylated
RNA was isolated using streptavidin magnetic beads. The degree of enrichment is calculated relative to the ratio of signals obtained in the total RNA.
(N=3, mean 6 s.e.m.)
doi:10.1371/journal.pone.0022583.g004
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resulted in the depletion of this polymerase from the promoter of
muscle actin genes (Figure S3).
Transcription of muscle actin genes by spRNAP-IV might
provide an energy-dependent coupling between
mitochondria and nuclear transcription
To assess the biological meaning of transcription of energy-
dependent contractile muscle actin genes by spRNAP-IV, we
tested the possibility that muscle actin gene transcription is
coupled to ATP production in the mitochondria. Inhibition of
mitochondrial function by oligomycin alone repressed the basal
level expression of ACTG2, ACTA2-S, ACTA1, ACTC1, POLRMT,
and cytochrome b. Induced expression of muscle actins by
triptolide is down-regulated by oligomycin as well (Figure 6).
Inhibition of muscle actin genes and POLRMT is consistent with
the hypothesis that transcription of muscle actin genes is coupled
to energy production in the mitochondria.
Discussion
In this report, we report that smooth, cardiac, and skeletal
muscle actins are transcribed by nuclear form of mitochondrial
polymerase, spRNAP-IV. This is demonstrated both by insensi-
tivity to PolII inhibition and knockdown, sensitivity to spRNAP-IV
inhibition or knockdown, as well as binding of spRNAP-IV to the
promoter of muscle actin genes. As expression level can be affected
by transcription, RNA processing and RNA turnover rate, we also
used nuclear run-on transcription to demonstrate that muscle
genes are indeed transcribed by spRNAP-IV but not by PolII. The
combination of these various criteria is required to rule out RNA
stability or differential processing as the cause of insensitivity to
PolII inhibition. Microarray analysis alone showed many a-
amanitin or triptolide resistant genes but many of them could not
fulfill these criteria and therefore are not truly transcribed by
spRNAP-IV. Our data and that of Kravchenko et al., [1] thus
provide compelling evidence that some nuclear genes are
transcribed not by the conventional PolII transcription machinery
but by a fourth RNA polymerase, spRNAP-IV. Our results further
indicate that a specific group of genes, namely, muscle actin genes,
are specifically transcribed by spRNAP-IV and dependent on
mitochondria ATP production.
Actin genes are evolved from an ancestral cytosplasmic
prototype through gene duplication, with the muscle actin genes
evolved later on [5] through amino acid substitutions, loss and
acquisition of introns as well as the acquisition of different
regulatory sequences for tissue-specific expression [6]. Our data
suggest that muscle actin genes have acquired the promoter
element for spRNAP-IV during evolution. The cis-regulatory
elements responsible for spRNAP-IV-mediated transcription
remain to be elucidated.
Interestingly, these energy-dependent contractile muscle actin
genes are usually expressed at a higher level in organs with higher
number of mitochondrion, such as heart and smooth muscle.
Transcription of these genes by mitochondrial polymerase nuclear
isoform might provide an energy-dependent coupling between
mitochondria and nuclear transcription program for such tissues.
It is possible that the splicing reaction for producing spRNAP-IV is
the critical event in mitochondria-nucleus coupling. Further
analysis is required to assess the biological meaning of transcrip-
tion of nuclear genes by a truncated form of a mitochondrial
enzyme.
It is interesting that muscle actin genes and spRNAP-IV are
actually up-regulated by PolII inhibitors. Similar finding for
ZBTB1, MGC3265 and ALDH12 was observed by Kravchenko
et al., [1]. The up-regulation of muscle actin genes could be due to
the de-regulation of POLRMT gene after triptolide or a-amanitin
treatment. Examination of POLRMT gene shows that its
transcription converges with HCN2 gene, which is transcribed by
PolII. Inhibition of HCN2 transcription may thus relieve the
interference of the converging transcription. The presence of some
PolII in the 59 region of muscle actin genes may represent the
interfering PolII transcription, and inhibition of PolII thus could
also account for the up-regulation of muscle actins. We believe
that the PolII found in the 59 region of muscle actin genes does not
participate in transcription of these genes, since knockdown of
PolII did not affect their transcription in vitro or expression level in
vivo. Our preliminary results suggest that several muscle actin
genes may have antisense transcription in or near these genes, and
thus inhibition of PolII could relieve the interference of these
antisense transcriptions on muscle actin gene expression.
The biological significance of transcription of nuclear genes by a
truncated form of mitochondrial polymerase is still unclear at
present. Mitochondria-nucleus communication and crosstalk has
been shown from yeast to plants and mammalian cells, [7] and
retrograde regulation of nuclear genes by mitochondria has been
well documented [8,9]. Genes transcribed by spRNAP-IV might
participate in such crosstalk. It is interesting that all the muscle
actin genes contain in their promoters SRF binding site, which has
been found in the promoters of genes involved in mitochondria
biogenesis such as PGC-1a and muscle contraction [10].
It is interesting that our data show that POLRMT, which
encodes mitochondrial RNA polymerase, is itself transcribed by
spRNAP-IV, forming a plausible feedback loop. Since Krav-
chenko et al., have shown that full-length mitochondria RNA
polymerase is not present in the nucleus [1], nuclear isoform of
mitochondria (spRNAP-IV) is the most likely candidate that serves
as a factor for nucleus-mitochondria communication and coupling
through differential splicing of the primary transcript of POLRMT.
Materials and Methods
Cell culture and Treatments
MCF-7, MDA-MB-231, MDA-MB-435s, MCF-10F cell lines
were originally obtained from ATCC (Manassas, VA). MCF-7
cells were cultured in RPMI medium supplemented with 10%
fetal bovine serum. MDA-MB-231 and MDA-MB-435s cells were
cultured in DMEM medium supplemented with 10% fetal bovine
serum. MCF-10F cells were cultured in a volume of 1:1 mixture
of DMEM and F12 medium, supplemented with 20 ng/ml
epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml
insulin, 500 ng/ml hydrocortisone, and 5% horse serum (Sigma).
All cell lines were incubated in a humidified 37uC incubator with
5% CO2. HUVSMC cell line was originally obtained from Cell
Applications, Inc. HUVSMC cells were routinely passaged and
maintained in smooth muscle cell growth medium (Cell
Applications, Inc.). To determine the inhibition of PolII
transcription, cells were cultured in the presence of 10 mg/ml
of a-amanitin or 0.3 mM of triptolide (Sigma) for 48 or 24 h,
respectively.
RNA extraction and Affymetrix
Total RNA was extracted according to the RNeasyH Mini Kit
Spin Protocol (QIAGEN). Affymetrix microarray was performed
using Human U133 plus 2.0 (Affymetrix). Details of the methods
for RNA quality, sample labeling, hybridization and expression
analysis were according to the manual of Affymetrix Microarray
Kit.
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immunoprecipitation. Chromatin immunoprecipitation with anti-PolII (IP-PolII) and anti-spRNAP-IV (IP-spRNAP-IV) was performed in MCF-7 cells
treated with or without 0.3 mM of triptolide for 24 h. DNA isolated from immunoprecipitated chromatin was subjected to PCR to amplify DNA
fragments. Nonimmune immunoglobulin G (IgG) -immunoprecipitated DNA was used as the control. The degree of enrichment is calculated relative
to the ratio of signals obtained in the input DNA fractions. Green lines indicate CpG islands. Orange arrows indicate the first exon of each gene.
Significant spRNAP-IV binding was detected in MCF-7 cells for (A) ACTG2 and (B) ACTA2-S promoters treated with or without triptolide. spRNAP-IV or
PolII occupancy was not observed in promoters of (C) ACTB and (D) TAF5 after triptolide treatment. Data are the means 6 standard errors of the
means (s.e.m.) from three independent experiments. Significant spRNAP-IV binding was also detected in HUVCMS cells for (E) ACTG2 and (F) ACTA2-S
promoters treated with or without triptolide. spRNAP-IV or PolII occupancy was not observed in promoter of (G) ACTB after triptolide treatment. M:
Marker.
doi:10.1371/journal.pone.0022583.g005
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All Affymetrix data is MIAME compliant and that the raw data
has been deposited in a MIAME compliant database, GEO. The
microarray data were deposited at the NCBI GEO website (GEO
accession number GSE30350).
Reverse Transcription and Quantitative Real-Time PCR
Reverse transcription was performed by using superScript
TM III
RNase H - Reverse Transcriptase (Invitrogen). Total cDNA was
then synthesized by means of Oligo(dT)15 or random hexamer
primed reverse transcription of captured molecules. Quantitative
PCR (q-PCR) was performed using SYBR Green dye on Roche
Applied Science LightCyclerH 2.0 Real-Time PCR System. All
reactions were performed in triplicate with SYBR Green Master
Mix (Sigma) plus 20 mM of both the forward and reverse primer
according to the manufacturer’s recommended thermocycling
conditions, and then subjected to melting curve analysis. The
calculated quantity of the target gene for each sample was divided
by the average sample quantity of the housekeeping genes,
glyceraldehydes-3-phosphate dehydrogenase (GAPDH)o r28S to
obtain the relative gene expression.
Run-on assay
Nuclear run-on reactions were performed by supplying biotin-
16-UTP to nuclei, and labeled transcripts were bound to
streptavidin-coated magnetic beads as described by Patrone G.
et al. 2000 [11] with minor modifications. Nuclei were prepared
from MCF-7 cells by resuspension in Nonidet P-40 lysis buffer
(10 mM HEPES, pH 7.3, 10 mM NaCl, 3 mM MgCl2, 150 mM
sucrose, and 0.5% Nonidet P-40). Nuclei were isolated, and the
pellets were resuspended in 1 ml of glycerol buffer (50 mM Tris-
Cl, pH 8.3, 40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA).
1 ml of transcription buffer (20 mM Tris-Cl, pH 8.0, 200 mM
KCl, 5 mM MgCl2, 4 mM dithiothreitol, 4 mM each of ATP,
GTP, and CTP, 200 mM sucrose, and 20% glycerol) was added in
the nuclei along with 10 ml of biotin-16-UTP or UTP for run-on
reaction or negative control, respectively (Roche Diagnostics).
After incubation at 29uC for 30 min, the reaction was terminated
by the addition of 6 ml of 250 mM CaCl2, and 6 ml of RNase-free
DNase I and incubated at 29uC for 10 min. To purify RNA, a
TRIreagent extraction, phenol-chloroform extraction, and isopro-
panol (Sigma) precipitation were then performed. A small aliquot
(5 ml from a total of 50 ml) was saved as ‘‘total nuclear RNA’’ for
each treatment. Dynabeads M-280 streptavidin (Dynal Biotech)
were mixed with an equal volume of the isolated RNA samples for
20 min at 42uC for 20 min and 2 h at room temperature. After
washing with 15% formamide and 2X SSC, the beads were
resuspended in 45 ml of nuclease-free water. Reverse transcription
was performed by using superscript
TM III RNase H - Reverse
Transcriptase (Invitrogen). Total cDNA was then synthesized by
means of random hexamer primed reverse transcription of
captured molecules.
SiRNA knockdown assay
SiRNA knockdown assay was performed according to the
manufacturer’s protocol (pSUPER RNAi System, OligoEngine)
[12]. Inhibition of expression of PolII or POLRMT was achieved
by transfection with pSUPER vector constructs expressing hairpin
siRNAs controlled by H1 RNA gene promoter. The following
19 bp regions corresponding to appropriate mRNAs were present
in the hairpin transcripts: exon 5 of POLRMT gene, 59 –
GATCCCCCACCTCCAAGCTGCTCAGGTTCAAGAGACC-
TGAGCAGCTTGGAGGTGTTTTTA – 39 and 59–AGCT-
TAAAAACACCTCCAAGCTGCTCAGGTCTCTTGAACCT-
GAGCAGCTTGGAGGTGGGG – 39; exon 17 of POLRMT
gene, 59 – GATCCCCCTTCATCCACTCGCTGGACTTCAA-
GAGAGTCCAGCGAGTGGATGAAGTTTTTA – 39 and 59 –
AGCTTAAAAACTTCATCCACTCGCTGGACTCTCTTGA-
AGTCCAGCGAGTGGATGAAGGGG – 39; PolII large subunit
(POLR2A), 59 – GATCCCCCCTCTCCAAGCTACTCTCCTT-
CAAGAGAGGAGAGTAGCTTGGAGAGGTTTTTA – 39 and
59 – AGCTTAAAAACCTCTCCAAGCTACTCTCCTCTC-
TTGAAGGAGAGTAGCTTGGAGAGGGGG – 39. The puri-
fication of plasmid DNA was performed according to the
QIAprepH Spin Miniprep Kit Instruction Manual (QIAGEN).
Cells were transfected using Lipofectamine
TM LTX according to
the instructions of the manufacturer (Invitrogen). Cells were
transfected in serum-free medium. After 20 h, the siRNA
containing medium was replaced with complete medium.
Chromatin Immunoprecipitation (ChIP)
ChIP assay was performed according to the manufacturer’s
protocol (Upstate Biotechnology, Inc., Lake Placid, NY) except
that sonication condition was changed to 45 times for 1 secs each
at 3W output. Human MCF-7 cells were fixed for 10 min with 1%
formaldehyde. The cells were lysed and the chromatin sonicated to
200–1000 bp fragments. Chromatin was immunoprecipitated by
using mtRNAP/spRNAP-IV (ab93102, abcam) or RNA polymer-
ase II antibody (ab5131, abcam), and Protein A Agarose beads.
The beads were washed once with each washing buffer, including
low salt immune complex wash buffer, high salt immune complex
wash buffer, and LiCl immune complex wash buffer, and twice
with 1X TE buffer. Precipitates were eluted with 1% of SDS and
100 mM of NaHCO3. The samples were heated at 65uC for 6 h in
order to reverse cross-link, extracted with phenol/chloroform,
ethanol-precipitated. Then PCR amplification was performed.
Luciferase assay
The promoter regions of ACTG2, ACTA2-S, and TAF5 were
cloned into the pGL3-basic Reporter Vector (Promega). MCF-7
cells were transfected using Lipofectamine
TM LTX according to
the instructions of the manufacturer (Invitrogen). The plasmids
Figure 6. Muscle actin genes are repressed by oligomycin.
Quantitative RT-PCR of actins in MCF-7 cells untreated or treated with
oligomycin, triptolide, or both drugs. To determine the affect of
oligomycin, cells were cultured in the presence of 10 mg/ml of
oligomycin for 24 hours. Triptolide was treated to the cells for 20 hours
prior RNA extraction. The basal expression of muscle actins was
repressed by oligomycin. Induction of muscle actin genes by triptolide
was down-regulated in the presence of oligomycin. In contrast, the
expression of ACTA2-L and ACTG1 non-muscle actin genes showed
increased expression under the presence of oligomycin and is repressed
by triptolide. Oligomycin had no significant affect on ACTB. A relative
expression normalized over RPS13 is displayed. (N=3, mean 6 S.D.)
doi:10.1371/journal.pone.0022583.g006
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for 24 h. Post 30 h of incubation, the cells were lysed and
luciferase assay was conducted using the Luciferase Assay System
(Promega) using a fluorimetric plate reader.
In vitro Transcription System
In vitro transcription was performed by using HeLaScribe
R
Nuclear Extract in vitro Transcription System (Promega Cat.#
E3110) according to the manufacturer’s protocol with slight
modifications. Anti-RNA polymerase II [PolII (ab5131, abcam)],
anti-mitochondrial RNA polymerase [mtRNAP-1 (ab32954,
abcam) and mtRNAP-2 (ab93102, abcam)] and anti-IgG (IgG)
antibodies were each pre-incubated with nuclear extract and
30 mg of yeast tRNA for 15 min. In vitro transcription was
performed by incubation with both linear forms of pGL3 plasmids
containing either upstream promoter regions of ACTG2 or TAF5
genes used in Luciferase assay, and GTP, CTP, ATP, and biotin-
16-UTP (Roche Diagnostics). Negative control was performed by
incubation with non biotin labeled NTPs. After incubation at
30uC for 1 h, the reaction was terminated by the addition of
175 ml of HeLa Extract Stop Solution (Promega Cat.# E3110).
To purify RNA, a TRIreagent extraction, phenol-chloroform
extraction, and isopropanol (Sigma) precipitation were then
performed. A small aliquot (2 ml from a total of 22 ml) was saved
as ‘‘total nuclear RNA’’ for each condition. The biotinylated RNA
was isolated using streptavidin-coated magnetic beads as described
in Run-on assay. Reverse transcription was performed by using
superscript
TM III RNase H - Reverse Transcriptase (Invitrogen).
Total cDNA was then synthesized by means of random hexamer
primed reverse transcription of captured molecules.
Supporting Information
Figure S1 Muscle actin genes are resistant and stimu-
lated by a-amanitin and triptolide. (A) Quantitative RT-
PCR of actin genes in MCF-7 cells treated with increasing
concentrations of a-amanitin for 48 h. A relative expression
normalized over 28s is displayed. (N=3, mean 6 S.D.) (B)
Quantitative RT-PCR of actin genes in MCF-7 cells treated with
increasing concentrations of triptolide for 24 h. A relative
expression normalized over GAPDH is displayed. (N=3, mean
6 S.D.) Quantitative RT-PCR of actin genes in (C) MCF-10F
cells (D) MDA-MB-231 cells (E) MDA-MB-435s cells (F)
HUVSMC cells treated with or without 0.3 mM of triptolide for
24 hours. The experiment was performed three independent times
and a relative expression normalized over GAPDH is displayed.
(N=3, mean 6 S.D.)
(TIF)
Figure S2 Strong induction of muscle actin genes by
TNF-a was resistant to PolII inhibitor. Quantitative RT-
PCR of actin genes in MCF-7 cells untreated or treated with TNF-
a, triptolide, or both drugs. To determine the inhibition of PolII
transcription, cells were cultured in the presence of 0.3 mMo f
triptolide for 24 hours. TNF-a was treated to the cells for 2 hours
prior RNA extraction. Muscle actin genes were strongly up-
regulated under TNF-a, triptolide, and both drug treatments.
Induction of muscle actin genes by TNF-a was resistant to
triptolide. In contrast, non-muscle actin genes, PolII and TAF5
showed decreased expression under the presence of triptolide. A
relative expression normalized over GAPDH is displayed. (N=3,
mean 6 S.D.)
(TIF)
Figure S3 Knockdown of POLRMT resulted in the
depletion of this polymerase from the promoter of
ACTA2-S. Chromatin immunoprecipitation with anti-spRNAP-
IV (IP-spRNAP-IV) was performed in MCF-7 cells transient
transfected with pSUPER-control (Si-control) or knockdown of
POLRMT (Si-POLRMT) plasmid. DNA isolated from immuno-
precipitated chromatin was subjected to PCR to amplify DNA
fragments. Nonimmune immunoglobulin G (IgG)-immunoprecip-
itated DNA was used as the control. Significant spRNAP-IV
binding was detected in MCF-7 cells for ACTA2-S promoter in
knockdown control, but knockdown of spRNAP-IV resulted in the
depletion of this polymerase from the promoter. M: Marker.
(TIF)
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